Products & Services · Milestone payment to be made
Adcirca — Milestone payment to be made
United Therapeutics Adcirca — Milestone payment to be made remained flat by 0.0% to $81.25K in Q4 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $81.25K to $81.25K. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ1 2024
Last reportedQ4 2025
How to read this metric
An increase in future milestone obligations may signal upcoming product development success or expansion, but also represents a future cash outflow.
Detailed definition
Reflects future financial obligations triggered by the achievement of specific development, regulatory, or commercial mi...
Peer comparison
Standard contingent liability reporting for pharmaceutical companies with in-licensed drug portfolios.
Metric ID:
uthr_segment_adcirca_milestone_payment_to_be_madeHistorical Data
2 years
| FY'24 | FY'25 | |
|---|---|---|
| Value | $325.00K | $325.00K |
| YoY Change | — | +0.0% |
Range$325.00K – $325.00K
Avg YoY Growth+0.0%
Median YoY Growth+0.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's adcirca — milestone payment to be made?
- United Therapeutics (UTHR) reported adcirca — milestone payment to be made of $81.25K in Q4 2025.
- How has United Therapeutics's adcirca — milestone payment to be made changed year-over-year?
- United Therapeutics's adcirca — milestone payment to be made decreased by 0.0% year-over-year, from $81.25K to $81.25K.
- What does adcirca — milestone payment to be made mean?
- Future one-time payments owed to partners upon reaching specific product development or sales goals.